| Stage | MDT | % of rev | MCK | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $9.8B | 100.00% | $111B | 100.00% | MCK ×11.37 |
| Gross profit | $6.3B | 64.99% | $4.0B | 3.57% | MDT +61.4pp |
| Operating income | $1.8B | 18.08% | $1.6B | 1.45% | MDT +16.6pp |
| Pre-tax income | $1.8B | 18.13% | $1.6B | 1.41% | MDT +16.7pp |
| Net income | $1.5B | 15.16% | $1.3B | 1.17% | MDT +14.0pp |
| Stage | MDT | MCK | Gap · A − B |
|---|---|---|---|
| Revenue | $9.8B100.00% | $111B100.00% | MCK ×11.37 |
| Gross profit | 64.99%$6.3B | 3.57%$4.0B | MDT +61.4pp |
| Operating income | 18.08%$1.8B | 1.45%$1.6B | MDT +16.6pp |
| Pre-tax income | 18.13%$1.8B | 1.41%$1.6B | MDT +16.7pp |
| Net income |
| 15.16%$1.5B |
| 1.17%$1.3B |
| MDT +14.0pp |
MDT · DHC 10-KFeb 25 '25
“Medtronic, Inc. 201,522 3.1% 5,297 2.5% 2027 - 2028”
MCK · DHC 10-KFeb 25 '25
“McKesson Corporation 477,772 7.3% 3,823 1.8% 2028 - 2030”